NIRLEP KAUR: Open Payments
NPI 1245086487 · FLINT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$778 in 69 payments from 6 companies in 2025. Trend: 2023 $0 · 2024 $171 · 2025 $778
Food & beverage: $778
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 13 | $242 |
| ABBVIE INC. | 30 | $221 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $171 |
| Neurocrine BioSciences, Inc. | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
Products named: FANAPT, VRAYLAR, CAPLYTA, INGREZZA, REXULTI, UZEDY, UBRELVY.
Industry payments across MI — which companies pay providers there.
